Etesian Wealth Advisors Inc. Sells 2,860 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Etesian Wealth Advisors Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.4% during the fourth quarter, HoldingsChannel reports. The fund owned 12,708 shares of the biopharmaceutical company’s stock after selling 2,860 shares during the quarter. Etesian Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $1,174,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. YANKCOM Partnership purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC increased its position in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on GILD shares. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Wolfe Research initiated coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Oppenheimer boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. UBS Group raised their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Finally, BMO Capital Markets increased their price objective on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $98.39.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock worth $53,611,715. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $99.65 on Thursday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $100.51. The stock has a fifty day moving average of $92.71 and a 200 day moving average of $86.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market capitalization of $124.19 billion, a price-to-earnings ratio of 1,107.22, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.